In a Boulder, Colorado lab, scientists aren't just screening for molecules that bind to a disease target; they are instructing an AI to design compounds that perform specific, disruptive chemical reactions on the protein itself. This is the core of Think Bioscience's mission: to move drug discovery from a search for keys that fit a lock to the engineering of molecular tools that can actively dismantle it. This week, that ambitious vision secured substantial fuel with a $55 million venture round, announced on January 21, 2026.
The company, co-founded by CEO Rahul Dhanda and CTO Dr. Lena Voss, emerged from academic roots at the University of Colorado with a focus on functional, rather than just structural, drug design. Their platform aims to tackle proteins considered 'undruggable' by traditional small-molecule approaches—targets without deep, well-defined pockets for a drug to nestle into. Think's AI models are trained on biochemical data to propose molecules that can catalytically modify these stubborn targets, offering a potential path to drugs for cancers and neurodegenerative diseases where options are limited.
This financing lands squarely in the midst of biotech's intensifying push into next-generation AI for drug discovery. While many platforms excel at predicting binding, Think is part of a newer vanguard focusing on mechanistic action and chemical reactivity. The bet is that this approach will yield higher-quality clinical candidates with better odds of success, a critical need as the industry seeks to improve dismal late-stage failure rates.
With the new capital, Think is advancing its lead programs toward the clinic. Key near-term milestones include selecting a development candidate for its lead oncology program and generating robust in vivo proof-of-concept data for a second asset, pivotal steps to test whether its computationally engineered molecules can deliver on their disruptive biochemical promise.